HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Pushes Back Profit Target in 5-Year Plan, Eyes Intensive Investment in Oncology
November 1, 2018
- Chugai Drops Herceptin Patent Suits against Daiichi Sankyo, Pfizer
November 1, 2018
- Daiichi Sankyo’s Half-Year Revenue Fell 4.8% as Generics Sap Olmesartan Sales
November 1, 2018
- Takeda Unveils Post-Acquisition Executive Team, 2 of 20 Members from Shire
November 1, 2018
- Takeda Sees Flat Sales as Brisk US Revenue Offset by Off-Patent Divestiture
November 1, 2018
- Biogen Japan COO Ajai Sulekh Named as New President
November 1, 2018
- Daiichi Sankyo to Discontinue Development of Intradermal Flu Vaccine
November 1, 2018
- Astellas Sales Up 1.1% Driven by Xtandi, OAB Drugs, despite Slump in Japan Business
November 1, 2018
- Sanofi, Daiichi Sankyo to Terminate Marketing Partnership for Hib Vaccine in Japan; Sanofi to Take Over Sales from Jan.
November 1, 2018
- Sumitomo Dainippon Operating Profit Plummets 50% on Drug Price Cut, Generic Erosions
October 31, 2018
- Mitsubishi Tanabe Sales Slip 1.7% as Radicava Boon Fails to Counter Japan Drop
October 31, 2018
- Mitsubishi Tanabe Paints Murky Outlook for US Sales Target on Parkinson’s Development Delay
October 31, 2018
- Nesp Biosame to Hit Japan Market in July-September 2019
October 31, 2018
- Otsuka Pharmaceutical Factory to Jointly Develop Regenerative Medicine Products with Startup
October 31, 2018
- Shionogi’s Half-Year Profits Renew Records, but Crestor Generics Weigh on Topline
October 30, 2018
- Shionogi Chief Confident about 70% Market Share for Xofluza in Japan
October 30, 2018
- Europe OKs Xtandi for All CRPC Cases
October 30, 2018
- JCR Initiates Development of Temcell for Epidermolysis Bullosa
October 30, 2018
- Takeda Mulls Sale of Shire GI Pipeline to Clinch European Clearance
October 29, 2018
- Fujifilm Signs MOU on Clinical Development of Favipiravir in China with 3 Chinese Partners
October 29, 2018
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
